Charles River Announces Second-Quarter 2008 Results

Downloadable version.

• Second-Quarter Sales Increase 14.5% to $352 Million
• Second-Quarter GAAP EPS Increase 29% to $0.71 and Non-GAAP EPS Increase 23% to $0.79
• Raising 2008 Sales and Non-GAAP EPS Guidance, GAAP EPS Guidance Lowered
• Agreement Signed to Acquire NewLab BioQuality AG
• Increases Stock Repurchase Authorization by $200 Million

WILMINGTON, Mass.--(BUSINESS WIRE)--Aug. 5, 2008--Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter and first six months of 2008. For the quarter, net sales increased 14.5% to $352.1 million from $307.4 million in the second quarter of 2007. Both the Research Models and Services (RMS) and Preclinical Services (PCS) business segments reported significantly higher sales, with the RMS segment showing particular strength due to continued demand from pharmaceutical and biotechnology companies. Foreign exchange contributed 4.1% to the net sales growth.